AveXis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch AveXis and buy or sell other stocks, ETFs, and their options commission-free!

About AVXS

AveXis , doing business as Novartis Gene Therapies, Inc., is a biotechnology company that specializes in the development and commercialization of gene therapies for patients and families affected by rare and life-threatening neurological genetic diseases. AveXis was acquired by Novartis on May 14, 2018. 

CEO
Sean P. Nolan
CEOSean P. Nolan
Employees
Employees
Headquarters
Bannockburn, Illinois
HeadquartersBannockburn, Illinois
Founded
2010
Founded2010
Employees
Employees

AVXS Key Statistics

Market cap
8.02B
Market cap8.02B
Price-Earnings ratio
-17.65
Price-Earnings ratio-17.65
Dividend yield
Dividend yield
Average volume
608.43K
Average volume608.43K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$217.94
52 Week high$217.94
52 Week low
$65.54
52 Week low$65.54

Stock Snapshot

The current AveXis(AVXS) stock price is $217.83, with a market capitalization of 8.02B. The stock trades at a price-to-earnings (P/E) ratio of -17.65.

During the trading day, AveXis(AVXS) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 608.43K.

The stock's 52-week range extends from a low of $65.54 to a high of $217.94.

The stock's 52-week range extends from a low of $65.54 to a high of $217.94.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.